Display options
Cite
Eckle I, Kolb G, Martin EM, et al. Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis. Mediators Inflamm. 1992;1(1):61-6doi: 10.1155/S0962935192000127.
Eckle, I., Kolb, G., Martin, E. M., & Havemann, K. (1992). Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis. Mediators of inflammation, 1(1), 61-6. https://doi.org/10.1155/S0962935192000127
Eckle, I, et al. "Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis." Mediators of inflammation vol. 1,1 (1992): 61-6. doi: https://doi.org/10.1155/S0962935192000127
Eckle I, Kolb G, Martin EM, Havemann K. Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis. Mediators Inflamm. 1992;1(1):61-6. doi: 10.1155/S0962935192000127. PMID: 18475443; PMCID: PMC2365317.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1992;1(1):61-6. doi: 10.1155/S0962935192000127.

Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis.

Mediators of inflammation

I Eckle, G Kolb, E M Martin, K Havemann

Affiliations

  1. Centre of Internal Medicine Philipps-University Baldinger Strasse Marburg D-355 Germany.

PMID: 18475443 PMCID: PMC2365317 DOI: 10.1155/S0962935192000127

Abstract

Cuprophane membranes during haemodialysis significantly increase the plasma levels of C5a(desArg) (maximal 55 mug C5a(adesArg)/1 blood after 30 min) whereas Hemophane or Polysulphonemembranes induce only low plasma levels of C5a(desArg). C5a(desArg) generated in vitro by yeast incubation of autologous plasma stimulates PMN chemotaxis and oxidative metabolism but has no effect on enzyme release. Preincubation of whole blood with C5a(desArg) causes aggregation and changed oxidative burst activity of the isolated PMN. These changes are similar to those found in cells from patients after haemodialysis with cuprophane membranes. So the elevated plasma levels of C5a(desArg) after haemodialysis explain some of the changes in PMN functions, but additional mechanisms have to be assumed.

References

  1. Nephrol Dial Transplant. 1988;3(6):773-83 - PubMed
  2. Kidney Int. 1983 Dec;24(6):764-9 - PubMed
  3. J Lab Clin Med. 1981 Dec;98(6):823-30 - PubMed
  4. Scand J Clin Lab Invest. 1985 Dec;45(8):759-66 - PubMed
  5. Agents Actions. 1989 Jun;27(3-4):380-4 - PubMed
  6. Am J Nephrol. 1985;5(5):320-6 - PubMed
  7. Blood. 1980 May;55(5):777-83 - PubMed
  8. Int J Artif Organs. 1989 May;12(5):294-8 - PubMed
  9. Agents Actions. 1983 Apr;13(2-3):218-21 - PubMed
  10. Blood. 1980 Jun;55(6):898-902 - PubMed
  11. Crit Rev Immunol. 1981 Feb;1(4):321-66 - PubMed
  12. Clin Nephrol. 1988 Mar;29(3):129-36 - PubMed
  13. J Clin Invest. 1977 Jul;60(1):260-4 - PubMed
  14. Clin Nephrol. 1988 Jun;29(6):307-11 - PubMed
  15. Nephron. 1989;51(3):320-4 - PubMed
  16. J Immunol Methods. 1988 Jul 22;111(2):241-52 - PubMed
  17. Clin Nephrol. 1986 Jun;25(6):304-7 - PubMed
  18. Proc Eur Dial Transplant Assoc. 1983;19:159-67 - PubMed
  19. Infect Immun. 1987 Mar;55(3):568-71 - PubMed
  20. Kidney Int. 1985 Aug;28(2):158-67 - PubMed
  21. Blood. 1982 Dec;60(6):1283-9 - PubMed
  22. J Clin Invest. 1982 Dec;70(6):1177-83 - PubMed
  23. Nephrol Dial Transplant. 1991;6(3):193-7 - PubMed
  24. Am J Nephrol. 1990;10(1):53-7 - PubMed
  25. Clin Immunol Immunopathol. 1978 Oct;11(2):196-211 - PubMed
  26. J Clin Invest. 1977 May;59(5):879-88 - PubMed
  27. J Infect Dis. 1990 Feb;161(2):242-9 - PubMed
  28. J Clin Invest. 1975 Nov;56(5):1155-63 - PubMed
  29. Artif Organs. 1984 Aug;8(3):281-90 - PubMed
  30. Int J Artif Organs. 1988 Mar;11(2):111-8 - PubMed
  31. Int J Artif Organs. 1990 Nov;13(11):729-36 - PubMed
  32. J Clin Invest. 1980 Aug;66(2):167-75 - PubMed
  33. J Clin Invest. 1973 Mar;52(3):741-4 - PubMed
  34. Mol Immunol. 1980 Feb;17(2):151-61 - PubMed
  35. Biochim Biophys Acta. 1959 Jul;34:255-6 - PubMed
  36. J Invest Dermatol. 1989 Feb;92(2):184-9 - PubMed

Publication Types